December 31, 2025

 

The 2025 RAPS Regulatory Convergence highlighted major shifts shaping the future of global medical devices and in vitro diagnostic (IVD) regulation. As regulatory systems evolve toward more data-driven, AI-enabled, lifecycle-focused oversight, manufacturers are facing increasing pressure to modernize compliance strategies, strengthen clinical evidence generation, and improve global regulatory agility.

This year’s discussions reflected a rapidly transforming regulatory environment where digitalization, artificial intelligence, usability engineering, post-market surveillance, and global harmonization are becoming central pillars of compliance.

For medical device manufacturers, regulatory affairs teams, software developers, and quality leaders, the event reinforced one critical message: proactive regulatory intelligence and strategic planning are now essential for maintaining global market access.

At Maven Regulatory Solutions, we continuously monitor international regulatory developments to help manufacturers navigate evolving expectations across FDA, EU MDR, IVDR, AI governance frameworks, and emerging global regulatory systems.

Why RAPS Regulatory Convergence Matters

The Regulatory Affairs Professionals Society (RAPS) Regulatory Convergence remains one of the most influential global events for regulatory professionals in the healthcare and medical technology sectors.

The conference provides insight into:

  • Emerging regulatory priorities 
  • Global policy direction 
  • Medical device compliance trends 
  • AI and software governance expectations 
  • Future regulatory modernization initiatives 
  • Cross-market harmonization strategies 
  • Evolving clinical and post-market evidence requirements 

The 2025 event particularly emphasized the convergence of digital innovation, patient-centricity, and lifecycle-based regulation.

1. Key Themes from the Plenary Sessions

The plenary sessions focused heavily on improving communication, transparency, usability, and patient-centered regulation.

Regulators, clinicians, and industry leaders emphasized that modern compliance now extends beyond technical conformity and increasingly includes:

  • User comprehension 
  • Human factors integration 
  • Real-world usability 
  • Clinical workflow compatibility 
  • Transparent risk communication 

Patient-Centric Communication Is Becoming A Regulatory Priority

A major theme involved the growing expectation for manufacturers to provide clearer and more accessible information to healthcare professionals and patients.

Regulatory Focus Areas Included

  • Improved Instructions for Use (IFU) design 
  • Better readability and usability 
  • Enhanced labeling communication 
  • Simplified risk explanations 
  • More intuitive digital information delivery 

Regulators increasingly expect manufacturers to demonstrate that users can understand device instructions, warnings, and intended use scenarios effectively.

Human Factors Engineering Is Expanding in Importance

The conference reinforced that usability engineering is no longer viewed as optional.

Key Industry Trends Included

  • Greater clinician involvement in early design 
  • Expanded human factors testing 
  • Increased use of rapid prototyping technologies 
  • Integration of 3D printing into device development 
  • User-centered iterative design methodologies 

Manufacturers are now expected to demonstrate that product usability directly supports patient safety and clinical effectiveness.

2. Europe, AI, And the Future of Medical Device Regulation

European regulation remained one of the most discussed topics throughout the conference.

Technical sessions focused heavily on:

  • EU MDR implementation challenges 
  • IVDR transition pressures 
  • EUDAMED evolution 
  • Artificial Intelligence Act readiness 
  • Software as a Medical Device (SaMD) governance 
  • Lifecycle regulatory data management 

The European regulatory framework continues to evolve rapidly, creating both challenges and opportunities for global manufacturers.

EU MDR And IVDR Updates Continue to Reshape Compliance

Stakeholders discussed ongoing concerns surrounding:

  • Legacy device transition pathways 
  • Notified body capacity 
  • Clinical evidence expectations 
  • PMCF obligations 
  • Technical documentation complexity 
  • Post-market performance requirements 

Manufacturers are increasingly expected to maintain dynamic, continuously updated regulatory systems rather than static submission-based compliance models.

Growing Focus On AI-Enabled Medical Devices

Artificial intelligence and machine learning regulation represented a major focus area at RAPS 2025.

Regulatory Concerns Included

  • Algorithm transparency 
  • Bias mitigation 
  • Continuous learning systems 
  • Data governance 
  • AI lifecycle monitoring 
  • Explainability requirements 
  • Cybersecurity integration 

Manufacturers developing AI-enabled devices should anticipate significantly higher regulatory scrutiny in 2026 and beyond.

EUDAMED And Regulatory Transparency

Sessions also highlighted the growing importance of EUDAMED in strengthening transparency and lifecycle oversight.

Key Areas of Discussion Included

  • Vigilance reporting integration 
  • Device traceability improvements 
  • Market surveillance coordination 
  • Clinical investigation transparency 
  • Digital regulatory submissions 

EUDAMED is expected to play an increasingly central role in European compliance infrastructure.

3. In Silico Modeling and Simulation (M&S)

One of the most forward-looking topics at the conference involved computational modeling and simulation technologies.

Regulators are increasingly recognizing the value of:

  • Digital twins 
  • Computational fluid dynamics 
  • Finite element modeling 
  • Physiological simulation 
  • Predictive computational testing 

These technologies support the broader trend toward model-informed regulatory decision-making (MIRDM).

Why In Silico Modeling Is Becoming Important

Modeling and simulation approaches may help manufacturers:

  • Reduce bench testing burden 
  • Minimize animal testing requirements 
  • Strengthening clinical evaluation strategies 
  • Improve benefit-risk justification 
  • Support PMCF activities 
  • Accelerate design optimization 

As validation frameworks mature, regulators are becoming more comfortable integrating computational evidence into decision-making processes.

4. Digital Transformation Across Regulatory Operations

The exhibit hall strongly reflected the industry’s shift toward digital regulatory operations and automation.

Organizations showcased technologies involving:

  • AI-powered regulatory intelligence 
  • Automated QMS workflows 
  • Digital technical documentation systems 
  • Regulatory change tracking platforms 
  • Predictive submission analytics 
  • Integrated global compliance dashboards 

Digital transformation is rapidly becoming essential for companies managing complex multinational regulatory obligations.

AI-Driven Regulatory Intelligence Is Expanding

Manufacturers are increasingly adopting AI-supported regulatory systems to manage:

  • Regulatory impact analysis 
  • Submission planning 
  • Global market access tracking 
  • Labeling updates 
  • Standards monitoring 
  • Vigilance trend analysis 

The complexity of global medical device regulation now requires continuous monitoring and rapid adaptation capabilities.

5. Strategic Recommendations for Manufacturers (2025–2026)

The discussions at RAPS 2025 highlighted several strategic priorities for manufacturers preparing for future regulatory expectations.

1. Strengthen Global Regulatory Intelligence Programs

Organizations should establish structured monitoring systems for:

  • FDA updates 
  • EU MDR/IVDR revisions 
  • AI Act implementation 
  • Global cybersecurity requirements 
  • Harmonized standards updates 
  • Post-market surveillance expectations 

Proactive intelligence gathering supports earlier risk identification and smoother compliance adaptation.

2. Enhance Clinical Evidence and Real-World Data Integration

Regulators increasingly expect stronger evidence throughout the product lifecycle.

Priority Areas Include

  • Real-world evidence collection 
  • PMCF integration 
  • Continuous performance evaluation 
  • Clinical data traceability 
  • Benefit-risk documentation 

Clinical evidence generation is becoming increasingly dynamic and continuous.

3. Modernize Quality and Documentation Systems

Manufacturers should invest in:

  • Digital QMS platforms 
  • Automated document control 
  • Traceability systems 
  • Data governance frameworks 
  • Lifecycle compliance management tools 

Digital readiness improves both operational efficiency and inspection preparedness.

4. Prepare For AI And Software Governance Expansion

AI-enabled and software-driven devices will face increasing regulatory attention globally.

Companies Should Focus On

  • AI transparency documentation 
  • Software lifecycle controls 
  • Cybersecurity integration 
  • Bias risk management 
  • Algorithm change governance 
  • Data integrity validation 

AI regulation is expected to expand substantially over the next several years.

5. Expand Risk Management Maturity

Risk management expectations are becoming more integrated across:

  • Design controls 
  • Clinical evaluation 
  • Supplier oversight 
  • Post-market surveillance 
  • Cybersecurity governance 
  • AI lifecycle management 

Manufacturers should ensure risk systems remain continuously updated and evidence based.

Emerging Global Regulatory Trends

The conference highlighted several broader global trends shaping the future of healthcare regulation.

  • Greater global harmonization 
  • Stronger Lifecycle Oversight 
  • Increased post-market scrutiny 
  • Expanded AI governance 
  • More patient-centric regulation 
  • Digital transformation of compliance systems 
  • Increased use of computational evidence 
  • Stronger Cybersecurity Expectations 
  • Enhanced transparency and traceability 

Manufacturers that adapt early will gain significant competitive advantages.

Why Global Regulatory Intelligence Matters More Than Ever

The pace of regulatory change is accelerating globally.

Organizations that rely on reactive compliance strategies may face:

  • Market access delays 
  • Submission deficiencies 
  • Increased audit findings 
  • Regulatory enforcement actions 
  • Product launch disruptions 
  • Higher remediation costs 

Strategic regulatory intelligence allows companies to anticipate changes before they become operational risks.

Quick Facts

  • RAPS 2025 emphasized AI, digital regulation, and lifecycle oversight 
  • EU MDR, IVDR, and AI Act developments dominated technical discussions 
  • Human factors, engineering and patient-centricity are becoming regulatory priorities 
  • In silico modeling is gaining recognition in regulatory decision-making 
  • Digital regulatory intelligence tools are expanding rapidly 
  • Cybersecurity and software governance expectations continue to increase 
  • Global harmonization remains a major regulatory objective 
  • Real-world evidence and PMCF expectations are growing across markets 

How Maven Regulatory Solutions Supports Global Regulatory Compliance

Our Services

  • Global regulatory intelligence monitoring 
  • EU MDR and IVDR compliance support 
  • FDA regulatory strategy development 
  • AI-enabled medical device compliance consulting 
  • Clinical evaluation and PMCF support 
  • Cybersecurity regulatory guidance 
  • Quality management system optimization 
  • Global market access strategy 
  • Risk management integration 
  • Technical documentation support 
  • EUDAMED readiness consulting 
  • In silico modeling regulatory strategy support 

Why Choose Maven Regulatory Solutions

  • Deep expertise across global medical device regulations 
  • Strong understanding of emerging AI governance frameworks 
  • Up-to-date regulatory intelligence capabilities 
  • Practical compliance and submission experience 
  • End-to-end lifecycle regulatory support 
  • Cross-functional expertise in quality, clinical, and regulatory affairs 
  • Strategic guidance for multinational market access 
  • Proactive regulatory risk management support 

Learn more at Maven Regulatory Solutions.

Need Support Navigating Global Regulatory Changes?

Maven Regulatory Solutions helps manufacturers prepare for evolving global regulatory expectations with confidence.

We Help You With

  • Regulatory intelligence monitoring 
  • EU MDR and IVDR strategy 
  • AI-enabled device compliance 
  • PMCF and clinical evidence planning 
  • Digital QMS modernization 
  • Cybersecurity governance 
  • Global market access support 
  • Lifecycle regulatory planning 

Partner With Maven Regulatory Solutions To

  • Strengthen global compliance readiness
  • Improve regulatory agility
  • Reduce market access risk
  • Enhance lifecycle regulatory governance
  • Support AI and software compliance
  • Improve inspection preparedness

Contact Maven Regulatory Solutions today to strengthen your global regulatory strategy for 2026 and beyond.

Conclusion

The insights from RAPS Regulatory Convergence 2025 demonstrate that global medical device regulation is entering a new era defined by digitalization, AI governance, lifecycle evidence generation, and patient-centered compliance.

Manufacturers must move beyond reactive regulatory approaches and build proactive, intelligence-driven compliance systems capable of adapting to rapidly evolving global expectations.

Organizations that invest early in regulatory intelligence, digital transformation, clinical evidence modernization, and risk-based governance will be best positioned to maintain market access and operational resilience.

The future of medical device regulation will be increasingly connected, transparent, data-driven, and technology-enabled and strategic preparation will be critical for long-term success.

Maven Regulatory Solutions remains committed to helping manufacturers navigate this evolving regulatory landscape with clarity, confidence, and precision.

Frequently Asked Questions

1. What is RAPS Regulatory Convergence?

RAPS Regulatory Convergence is a leading global conference focused on healthcare and medical device regulatory affairs.

2. What were the biggest themes at RAPS 2025?

Key themes included AI regulation, EU MDR/IVDR updates, digital transformation, cybersecurity, lifecycle evidence, and regulatory harmonization.

3. Why is AI regulation becoming more important?

AI-enabled medical devices require stronger governance around transparency, risk management, algorithm control, and cybersecurity.

4. What is in silico modeling?

In silico modeling, computational simulations and digital models to support device testing, clinical evaluation, and regulatory evidence generation.

5. Why does regulatory intelligence matter?

Continuous regulatory monitoring helps manufacturers anticipate compliance changes, reduce risk, and maintain uninterrupted market access.

6. What is the importance of EUDAMED?

EUDAMED improves device traceability, vigilance reporting, and regulatory transparency across the European Union.

7. How can Maven Regulatory Solutions help?

Maven supports global regulatory intelligence, EU MDR/IVDR compliance, AI governance strategy, clinical evidence planning, cybersecurity readiness, and global market access.